Lumryz (Sodium Oxybate) Patent Expiration, LOE Window & CMS Spending

Lumryz (Sodium Oxybate) by Alkermes: FDA Orange Book LOE 2042-03-16, 0 AB generics, $16.1M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlkermes
FDA Application & PathwayN214755 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-03-16
Orange Book Patents (*PED Extensions)30 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$16.1M
2024 Medicare Part D Spend$16.1M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alkermes across sibling Meru public-data platforms.